Physician profile
Linda E Brown
NPI 1689761074
$4,370.39
in general payments reported to CMS, 2019-2025
22 companies · $772 in 2025
The $772 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $232 · 2020: $348 · 2021: $762 · 2022: $628 · 2023: $772 · 2024: $857 · 2025: $772.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,256 · Education: $145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,255.66 |
| Education | $144.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harmony Biosciences LLC | $1,080.01 | 2020-2025 | Wakix |
| Abbvie INC. | $965.97 | 2021-2025 | Qulipta, Ubrelvy |
| Jazz Pharmaceuticals INC. | $762.84 | 2019-2025 | |
| Axsome Therapeutics, INC. | $214.52 | 2022-2025 | Sunosi |
| Lilly USA, LLC | $189.54 | 2019-2025 | Zepbound |
| Teva Pharmaceuticals USA, INC. | $172.25 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $154.56 | 2021 | |
| Alexion Pharmaceuticals, INC. | $144.87 | 2019-2024 | Strensiq |
| Avadel Cns Pharmaceuticals, LLC | $131.53 | 2023-2024 | Lumryz |
| Amneal Pharmaceuticals LLC | $110.78 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $103.93 | 2022-2025 | Ingrezza |
| Pfizer INC. | $67.05 | 2023-2024 | |
| Vifor Pharma, INC. | $48.70 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $44.95 | 2021-2023 | Onpattro |
| Lundbeck LLC | $33.13 | 2021-2023 | Vyepti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $29.32 | 2022 | |
| Inspire Medical Systems, INC. | $28.77 | 2023 | Inspire |
| Amgen INC. | $19.86 | 2020 | |
| Idorsia Pharmaceuticals US INC | $18.27 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $18.00 | 2019 | |
| Supernus Pharmaceuticals, INC. | $15.99 | 2019 | |
| Merck Sharp & Dohme LLC | $15.55 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Linda Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.